# Krabbe Disease Treatment Market

> Krabbe Disease Treatment Market Research Report Therapeutics Information, by Types of treatments (anticonvulsant medication, physical therapy, muscle relaxer drugs, Bone Marrow Transplantation) by end users (Hospitals and Clinics, Research Centers, laboratories) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.17%
- **2024:** $ 2,500.32 Million
- **2025:** $ 2,708.24 Million
- **2035:** $ 5,378.58 Million
- **Key Players:** Sanofi (FR), Alexion Pharmaceuticals (US), Bluebird Bio (US), Orchard Therapeutics (GB), Sarepta Therapeutics (US), Amicus Therapeutics (US), Avexis (US), Genzyme (FR)

**Report ID:** MRFR/Pharma/1301-HCR · **Pages:** 80 · **Author:** Satyendra Maurya & Kinjoll Dey · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/krabbe-disease-treatment-market-1833

---

## Market Summary

## **Krabbe Disease Treatment Market Overview**

The krabbe disease treatment market is anticipated to reach USD 6.82 Billion by 2030 at 8.2% CAGR during the forecast period 2022-2030. Krabbe Disease can be considered as an inherited condition that tends to destroy the coatings of the nerve cells. They are known as Myelin. It is in the central nervous system and the brain. 

Krabbe disease is diagnosed in children that belong to the age group of 6 years of age. However, there is no cure for Krabbe disease; while this condition is managed by supportive care. Krabbe disease, as the market discussion is also known as globoid cell leukodystrophy. The stem cell transplants are showing promising market results in infants if they are provided treatment before the onset of the disease and spread of the disease based on their symptoms.

 A few signs and symptoms of Krabbe disease in infants range between frequent vomiting, feeding difficulties, fever, muscle spasms, and other symptoms like loss of head control. As the disease within the body progresses, many symptoms increase the degree of severity such as seizures, imbalance in developmental abilities, and others like the loss of hearing & sight, constricted muscles, and many more. If the Krabbe disease develops later in childhood or in stages of adulthood, there are few symptoms such as difficulty walking, vision loss, muscle weakness, are studied and identified.

**COVID 19 Analysis**

The sudden arrival and outbreak of the COVID 19 pandemic have pushed for new changes across various functions and departments of the industries, companies, and their units are taking time to adjust to the new change and implement strategies for growth and development accordingly. The Krabbe disease treatment market revenue has also been affected because of the arrival of the pandemic. The arrival of the global pandemic has introduced new trends and struggles to the Krabbe Disease Treatment market size.

This was an attempt by governments across the globe participating locations to stop the community’s spread of the fatal pandemic to protect people. Also, there are many restrictions like limited functioning and social distancing that have been imposed. These factors are hampering the online business and further, hurting the quick delivery system of the online markets.

The global governments are increasing their norms and support by increasing the investment in the research and development sector of the market that will help to produce a huge variety of market products and services. The main aim behind is this that it will help enhance the global portfolio for the market. Also, the role of public authorities is prominent that making them available for a larger audience through various segments and distribution channels. The key and propelling market players are also expanding their services in both the regional and international markets for global growth during the ongoing forecast period.

## **Krabbe Disease Treatment Market Trends**

**Drivers**

There has been an increasing degree of awareness about Krabbe disease which is a rare genetic disorder. The market is filled with equipment and standard tools for the diagnosis of Krabbe disease. Also, the market is witnessing a huge degree of growing research & developmental activities that are emerging as a few prominent factors that are likely to boosts the market during the forecast period. Their market and the prominent market players followed by the healthcare professionals are offering services like imaging scans, nerve conduction, eye examination, and many others like genetic testing.

These are a few prominent factors that are estimated to propel the Krabbe disease treatment market during the forecast period.

**Restraints**

However, the market has some restraints on the way during the period that aim for its expansion. The global market is witnessing the emergence of market factors like the availability of a limited patient pool for clinical trials. These issues are collaborating with others like the rising unavailability of information and awareness might hamper the expansion goals of the market for the ongoing forecast period by the business chiefs and analysts.

The arrival of the pandemic has been another issue that is diverting the attention of the medical professionals to treat the patients and juggle between the ones who have tested positive for the virus and the ones that are suffering from the Krabbe disease.

The Krabbe disease treatment market is expanding significantly owing to the introduction of special drug designation and similar trends are being highlighted for the ongoing forecast period. The market is witnessing the rise of biologics which is considered to be a safe and effective treatment of the disease. There has been a global introduction of gene technology that has showcased promising results in the treatment of the disease. Also, the global market is further, witnessing a substantial increase in clinical development of the treatment for the Krabbe disease.

There has been a huge rise in investment in research and development activities that are major factors that are projected to boost the global market in the next few years.

## **Krabbe Disease Treatment Market Segment Insights**

The krabbe disease treatment market is projected to witness an excellent market CAGR owing to the rising needs of the global target audience. The market has been segmented based on various sub-segments that will help in the market expansion are mentioned as follows:

### **Krabbe Disease Treatment Disease Type Insights**

### **Krabbe Disease Treatment Insights**

### **Krabbe Disease Treatment Distribution Channel Insights**

### **Krabbe Disease Treatment Regional Insights**

Based on the regional segmentation of the krabbe disease treatment market, the North American had accounted for a notable share of the krabbe disease treatment market followed by Europe during the historic forecast period that had ended in 2018, and similar trends are expected for the ongoing forecast period that will be ending in 2030. The global market trends also highlight that there is a rapid rate of adoption of highly developed technologies and innovative drugs for the management of Krabbe disease and treatment of people that are suffering from the Krabbe disease.

These are a few factors that are likely to drive the Krabbe disease treatment market during the forecast period.

## **Krabbe Disease Treatment Market Competitive Landscape**

The krabbe disease treatment market is propelling in the international market owing to the functions undertaken by the prominent market players that are mentioned as follows as discussed for the ongoing forecast period.

**Recent Developments**

The viable presence of the key companies in the European region are offering medication and other therapies for the complication and symptoms of Krabbe disease, especially in the infant group, are a few factors that are anticipated to boost the market in Europe during the ongoing forecast period of 2022-2030.

There are a lot of various organizations functioning together in Europe for the identification of the gene mutation and creating awareness about Krabbe disease. This prominent market factor is also projected to propel the market in Europe during the forecast period.

In the U.S., as a part of the North American region, the Krabbe disease is likely to affect around 1 in 100,000 population. The global region is witnessing the advent of technological advancements that have led to the development of treatment to manage Krabbe disease.

**Report Overview**

The Krabbe disease treatment market report has been prepared to have a basic understanding of the market functions that were on the loop before the pandemic hit and further, helps in understanding the changes that were introduced by the pandemic. Also, the global market report highlights the market functions in the form of the dynamics and the market segmentations that have been developed to meet the rising needs of the global target audience.

The report helps in understanding the market scope based on the recent developments and the rising market competition during the period ending in 2027 that is likely to have an impact on the investor's decisions and business chiefs followed by the corrective steps for a better tomorrow.

## Market Drivers

### Market Growth Projections

The Global Krabbe Disease Treatment Market Industry is poised for substantial growth in the coming years. Projections indicate that the market will reach 3.68 USD Billion in 2024, with an anticipated increase to 10.1 USD Billion by 2035. This growth trajectory suggests a robust compound annual growth rate (CAGR) of 9.62% from 2025 to 2035. Factors contributing to this expansion include advancements in treatment options, increased awareness, and a growing patient population. The market's evolution reflects the ongoing commitment to addressing the needs of individuals affected by Krabbe disease, highlighting the importance of continued investment in research and development.

### Advancements in Gene Therapy

Recent advancements in gene therapy are transforming the landscape of the Global Krabbe Disease Treatment Market Industry. Innovative approaches, such as enzyme replacement therapy and stem cell transplantation, are showing promise in treating this debilitating condition. These therapies aim to address the underlying genetic causes of Krabbe disease, potentially improving patient outcomes. As the market evolves, the introduction of new gene therapies is projected to contribute significantly to market growth, with an expected CAGR of 9.62% from 2025 to 2035. This growth underscores the importance of continued investment in research and development to bring effective treatments to market.

### Rising Awareness and Advocacy

The growing awareness and advocacy for rare diseases, including Krabbe disease, are significant drivers of the Global Krabbe Disease Treatment Market Industry. Advocacy groups are actively promoting education and awareness campaigns, which are crucial for increasing public knowledge about the disease and its impact. This heightened awareness is likely to lead to increased funding for research and development, as well as improved access to treatments for affected individuals. As the market continues to evolve, the influence of advocacy efforts is expected to contribute to its growth, with projections indicating a market value of 10.1 USD Billion by 2035.

### Enhanced Diagnostic Techniques

The evolution of diagnostic techniques is playing a vital role in the Global Krabbe Disease Treatment Market Industry. Improved screening methods, including newborn screening programs, are facilitating earlier detection of Krabbe disease. Early diagnosis is crucial for effective intervention, as timely treatment can significantly improve patient outcomes. The increased accuracy and accessibility of these diagnostic tools are expected to drive market growth, as more patients are identified and treated. This trend aligns with the overall growth trajectory of the market, which is projected to reach 3.68 USD Billion in 2024, emphasizing the importance of early intervention in managing rare diseases.

### Increasing Prevalence of Krabbe Disease

The rising incidence of Krabbe disease globally is a pivotal driver for the Global Krabbe Disease Treatment Market Industry. As awareness increases, more cases are being diagnosed, leading to a greater demand for effective treatments. In 2024, the market is projected to reach 3.68 USD Billion, reflecting the urgent need for innovative therapies. This trend is likely to continue, as the prevalence of rare genetic disorders like Krabbe disease is expected to rise, necessitating advancements in treatment options. The growing patient population is anticipated to propel the market further, highlighting the critical need for research and development in this field.

### Growing Investment in Rare Disease Research

The increasing investment in research focused on [rare diseases](https://www.marketresearchfuture.com/reports/rare-disease-treatment-market-43459) is a crucial driver for the Global Krabbe Disease Treatment Market Industry. Governments and private organizations are recognizing the need for targeted therapies for conditions like Krabbe disease. This financial support is fostering innovation and accelerating the development of new treatment options. As a result, the market is anticipated to expand significantly, with projections indicating a rise to 10.1 USD Billion by 2035. This influx of funding is likely to enhance collaboration among researchers, pharmaceutical companies, and healthcare providers, ultimately benefiting patients with Krabbe disease.

## Future Outlook

The Krabbe Disease Treatment Market is projected to grow at a 7.17% CAGR from 2025 to 2035, driven by advancements in gene therapy, increased awareness, and enhanced diagnostic capabilities.

**New opportunities:**

- Development of personalized gene therapy solutions for Krabbe Disease patients. Expansion of telehealth services for remote patient monitoring and consultations. Strategic partnerships with biotech firms for innovative treatment research and development.

By 2035, the Krabbe Disease Treatment Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Treatment Type: Enzyme Replacement Therapy (Largest) vs. Stem Cell Transplantation (Fastest-Growing)

In the Krabbe Disease Treatment Market, the segment values exhibit distinct shares and growth potential. Enzyme Replacement Therapy holds the largest market share due to its established efficacy and widespread acceptance among healthcare providers. This treatment method is well-integrated within clinical practices, contributing significantly to the overall market dynamics regarding Krabbe disease management. In contrast, Stem Cell Transplantation, while smaller in market share, is recognized as the fastest-growing segment. This recent rise is primarily driven by advancements in medical technologies and increasing clinical trials showcasing its potential benefits for patients.

Enzyme Replacement Therapy (Dominant) vs. Gene Therapy (Emerging)

Enzyme Replacement Therapy (ERT) continues to dominate the treatment landscape for Krabbe disease due to its proven effectiveness in managing symptoms and improving quality of life. This approach has become a standard care method, establishing itself as the go-to option for clinicians. On the other hand, Gene Therapy is considered an emerging treatment that aims to correct the underlying genetic defects causing Krabbe disease. With ongoing research and favorable clinical outcomes, Gene Therapy shows promise in the long run but still faces hurdles in terms of regulatory approvals and widespread acceptance. The evolution of Gene Therapy could reshape treatment paradigms in the coming years, making it a segment to watch closely in the market.

### By Patient Age Group: Infants (Largest) vs. Children (Fastest-Growing)

In the Krabbe Disease Treatment Market, the distribution of patients by age group shows that infants represent the largest segment, capturing a significant share due to the early onset of Krabbe disease. This age group often presents the most severe symptoms, leading to an urgent need for treatment options. Following infants, the children segment is notable and shows an increasingly important role, marking a shift in treatment strategies that address the nuances of Krabbe disease as children grow older and require ongoing care.

Infants (Dominant) vs. Children (Emerging)

Infants, as the dominant segment in Krabbe Disease treatment, necessitate immediate intervention due to the acute severity of the disease symptoms, typically manifesting within the first six months of life. Treatment options for this age group often include enzyme replacement therapy and hematopoietic stem cell transplantation, which have shown efficacy in halting disease progression. On the other hand, the children segment is emerging rapidly in importance as new treatment modalities are developed. This age group may have more options available due to advancements in therapeutic strategies, leading to a growing demand for tailored treatment plans that take past and future healthcare needs into consideration.

### By Administration Route: Intravenous (Largest) vs. Oral (Fastest-Growing)

In the Krabbe Disease Treatment Market, the administration routes are defined by their therapeutic efficacy and patient preference. Intravenous treatment currently holds the largest market share, favored for its rapid action and direct delivery into the bloodstream. Oral administration, on the other hand, is gaining traction due to its ease of use and patient compliance, establishing a significant, although smaller, share of the market. Subcutaneous routes are also present, though they currently have a lesser impact in terms of market share. Growth trends in the Krabbe Disease Treatment Market indicate a shift towards more patient-friendly administration options. Intravenous therapy remains essential for immediate intervention in acute cases, but the oral route is becoming popular among caregivers seeking more convenient administration options. Innovations in drug formulations are also expected to enhance the appeal of subcutaneous and oral routes, contributing to quicker adoption rates and significant growth in these areas moving forward.

Intravenous (Dominant) vs. Oral (Emerging)

Intravenous administration is the dominant route in the Krabbe Disease Treatment Market, primarily due to its ability to deliver medications effectively during critical phases of the disease. This method ensures that patients receive the necessary dosages quickly, which is crucial given the progressive nature of Krabbe Disease. In contrast, oral administration represents an emerging trend. Its attractiveness lies in the ease of administration, which increases adherence among patients and caregivers. With ongoing research focusing on oral formulations, this segment is expected to grow more rapidly as patients seek less invasive treatment regimens. Both administration routes must align with physician recommendations and patient needs to optimize treatment outcomes.

### By Healthcare Setting: Hospitals (Largest) vs. Specialized Clinics (Fastest-Growing)

In the Krabbe Disease Treatment Market, healthcare settings are primarily divided into hospitals, specialized clinics, and home care. Hospitals hold the largest share within this segment due to their comprehensive infrastructure, ability to provide intricate medical treatments, and accessibility to advanced medical technology. Specialized clinics, while smaller in terms of market share, are gaining traction as they focus on providing tailored treatments for rare diseases like Krabbe disease, increasing their visibility among healthcare providers and patients.

Hospitals (Dominant) vs. Specialized Clinics (Emerging)

Hospitals represent the dominant force in the Krabbe Disease Treatment Market, largely due to their established networks, advanced technology, and multidisciplinary teams. They provide a full spectrum of care including diagnosis, treatment, and post-treatment support. In comparison, specialized clinics are emerging players focusing exclusively on rare disorders, offering specialized care and personalized treatment protocols. The rise of specialized clinics is driven by the need for tailored medical services and patient-centric approaches, making them a vital complement to the comprehensive services offered by hospitals.

## Regional Market Share Analysis

### North America : Market Leader in Treatment

North America is poised to maintain its leadership in the Krabbe Disease treatment market, holding a significant share of approximately 1350.16 million, reinforcing its dominance in the krabbe disease treatment market share. The region benefits from advanced healthcare infrastructure, high R&D investments, and a growing awareness of rare diseases. Regulatory support from agencies like the FDA further accelerates the approval of innovative therapies, driving demand for effective treatments. The United States stands out as the primary market, with key players such as Sanofi, Alexion Pharmaceuticals, and Bluebird Bio leading the charge. The competitive landscape is characterized by a focus on gene therapies and enzyme replacement therapies, which are gaining traction. The presence of established pharmaceutical companies ensures a robust pipeline of treatments, catering to the needs of patients and healthcare providers alike.

### Europe : Emerging Market Potential

Europe is witnessing a growing demand for Krabbe Disease treatments, with a market size of 700.0M projected for 2025. Factors such as increasing healthcare expenditure, advancements in medical technology, and collaborative research initiatives are driving this growth. Regulatory bodies are also playing a crucial role in expediting the approval of innovative therapies, enhancing patient access to essential treatments. Leading countries like Germany, France, and the UK are at the forefront of this market, supported by a robust healthcare system and a focus on rare diseases. Key players, including Orchard Therapeutics and Amicus Therapeutics, are actively involved in developing therapies tailored to the European market. The competitive landscape is evolving, with a strong emphasis on partnerships and collaborations to enhance treatment options.

### Asia-Pacific : Growing Awareness and Demand

The Asia-Pacific region is emerging as a significant market for Krabbe Disease treatments, with a projected size of 400.0M by 2025. Factors such as increasing awareness of rare diseases, improving healthcare infrastructure, and rising disposable incomes are driving demand. Regulatory bodies are also becoming more proactive in approving treatments, which is crucial for market growth in this region. Countries like Japan and Australia are leading the way, with a growing number of clinical trials and research initiatives focused on Krabbe Disease. The competitive landscape includes both local and international players, with companies like Avexis and Genzyme making strides in developing effective therapies. The region's market is characterized by a focus on innovative treatment solutions that cater to the unique needs of patients.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region represents an untapped market for Krabbe Disease treatments, with a market size of 100.32M projected for 2025. The growth in this region is driven by increasing healthcare investments, rising awareness of rare diseases, and the need for improved healthcare services. Regulatory frameworks are gradually evolving to support the introduction of innovative therapies, which is essential for market expansion. Countries such as South Africa and the UAE are beginning to see a rise in demand for specialized treatments. The competitive landscape is still developing, with opportunities for both local and international companies to enter the market. Key players are focusing on establishing partnerships and collaborations to enhance treatment accessibility and improve patient outcomes.

## Competitive Benchmarking

The Krabbe Disease Treatment Market is characterized by a dynamic competitive landscape, driven by the urgent need for effective therapies for this rare genetic disorder, as highlighted in recent krabbe disease treatment market analysis. Key players are increasingly focusing on innovation and strategic partnerships to enhance their market presence. Key players are increasingly focusing on innovation and strategic partnerships to enhance their market presence. Companies such as Sanofi (FR), Alexion Pharmaceuticals (US), and Bluebird Bio (US) are at the forefront, leveraging their research capabilities and existing product portfolios to address the unmet medical needs associated with Krabbe disease. Their operational focus appears to be on developing novel therapies, expanding clinical trials, and exploring collaborations that could potentially accelerate the delivery of treatments to patients. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Genzyme (US) and Amicus Therapeutics (US) is significant, as they contribute to shaping the competitive dynamics through their innovative approaches and strategic initiatives.
In November Sanofi (FR) announced a collaboration with a leading academic institution to advance its gene therapy research for Krabbe Disease. This partnership is expected to accelerate the development of innovative treatment options, highlighting Sanofi's commitment to addressing unmet medical needs. Such collaborations not only enhance research capabilities but also position the company as a thought leader in the field.
In October Alexion Pharmaceuticals (US) launched a new initiative aimed at increasing awareness and access to treatments for Krabbe Disease. This initiative includes educational programs for healthcare providers and support for patient advocacy groups. By focusing on awareness, Alexion seeks to improve diagnosis rates and treatment accessibility, which could significantly impact patient outcomes and market penetration.
In September Bluebird Bio (US) received regulatory approval for its latest gene therapy aimed at treating Krabbe Disease. This approval marks a pivotal moment for the company, as it not only validates its innovative approach but also enhances its competitive positioning in the market. The successful launch of this therapy is likely to attract attention from investors and stakeholders, further solidifying Bluebird's role as a key player in the treatment landscape.
As of December the competitive trends in the Krabbe Disease Treatment Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This transition underscores the importance of not only developing effective treatments but also ensuring their accessibility and sustainability in the market.

## Recent News & Developments

The viable presence of the key companies in the European region are offering medication and other therapies for the complication and symptoms of Krabbe disease, especially in the infant group, are a few factors that are anticipated to boost the market in Europe during the ongoing forecast period of 2022-2030.

There are a lot of various organizations functioning together in Europe for the identification of the gene mutation and creating awareness about Krabbe disease. This prominent market factor is also projected to propel the market in Europe during the forecast period.

In the U.S., as a part of the North American region, the Krabbe disease is likely to affect around 1 in 100,000 population. The global region is witnessing the advent of technological advancements that have led to the development of treatment to manage Krabbe disease.

## Report Scope

| MARKET SIZE 2024 | 2500.32(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2708.24(USD Million) |
| MARKET SIZE 2035 | 5378.58(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.17% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Sanofi (FR), Alexion Pharmaceuticals (US), Bluebird Bio (US), Orchard Therapeutics (GB), Sarepta Therapeutics (US), Amicus Therapeutics (US), Avexis (US), Genzyme (FR) |
| Segments Covered | Treatment Type, Patient Age Group, Administration Route, Healthcare Setting |
| Key Market Opportunities | Advancements in gene therapy present transformative potential for the Krabbe Disease Treatment Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Krabbe Disease Treatment Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Krabbe Disease Treatment Market?**
A: The market valuation was approximately 2500.32 USD Million in 2024.

**Q: What is the projected market size for the Krabbe Disease Treatment Market by 2035?**
A: The market is expected to reach around 5378.58 USD Million by 2035.

**Q: What is the expected CAGR for the Krabbe Disease Treatment Market during the forecast period 2025 - 2035?**
A: The anticipated CAGR for the market is 7.17% from 2025 to 2035.

**Q: Which treatment types dominate the Krabbe Disease Treatment Market?**
A: Enzyme Replacement Therapy, Stem Cell Transplantation, Gene Therapy, and Supportive Care are key treatment types.

**Q: What was the market value for Stem Cell Transplantation in 2024?**
A: The market value for Stem Cell Transplantation was between 800.0 and 1800.0 USD Million in 2024.

**Q: How does the market for Krabbe Disease treatment vary by patient age group?**
A: In 2024, the market values ranged from 400.06 USD Million for Adolescents to 1710.86 USD Million for Children.

**Q: What are the leading companies in the Krabbe Disease Treatment Market?**
A: Key players include Sanofi, Alexion Pharmaceuticals, Orphazyme, and Bluebird Bio.

**Q: What administration routes are utilized in the Krabbe Disease Treatment Market?**
A: The market includes Intravenous, Oral, and Subcutaneous administration routes.

**Q: What healthcare settings are involved in the treatment of Krabbe Disease?**
A: Hospitals, Specialized Clinics, and Home Care are the primary healthcare settings for treatment.

**Q: What is the market value for Supportive Care in 2024?**
A: The market value for Supportive Care was between 600.32 and 878.58 USD Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/krabbe-disease-treatment-market-1833*